Fibroblast Growth Factors as Tools in the Management of Neuropathic Pain Disorders

2020 ◽  
Vol 21 (10) ◽  
pp. 1034-1043
Author(s):  
Fatemeh Forouzanfar ◽  
Hamid R. Sadeghnia

Neuropathic pain is caused by a damage to or dysfunction of the somatosensory nervous system. The main mechanisms underlying neuropathic pain include ectopic activity in nociceptive nerves, peripheral and central sensitization, impaired inhibitory modulation, and microglial activation. Fibroblast growth factors (FGFs) make up a large family of growth factors that mediate neural development, metabolism, and function through three main key signaling pathways, including RAS/MAP kinase pathway, PI3 kinase/Akt pathway, and PLCγ. An association between the members of the FGF system and the improvement of neuropathic pain has become evident, recently. These signaling molecules may be expected to provide new drug targets for the treatment of neuropathic pain. To the best of our knowledge, it is the first study that reviews the relationship between some members of the FGF system and neuropathic pain.

2012 ◽  
Vol 55 (12) ◽  
pp. 1038-1044 ◽  
Author(s):  
Xu Zhang ◽  
Lan Bao ◽  
Liu Yang ◽  
QingFeng Wu ◽  
Shuai Li

2010 ◽  
Vol 22 (1) ◽  
pp. 228
Author(s):  
M. I. Giassetti ◽  
Q. E. Yang ◽  
A. D. Ealy

Following hatching, bovine and ovine blastocysts elongate into tubular and then filamentous conceptuses that remain free-floating for several days before attaching to the uterine lining. Elongation is marked by trophectoderm proliferation and changes in trophectoderm shape. The ultimate goal of this work is to identify uterine- and conceptus-derived factors that control peri-attachment conceptus development in cattle. Fibroblast growth factors (FGF) encompass a large family of mitogens, morphogens, and angiogenic factors produced by various tissues, including the bovine/ovine endometrium and conceptus. FGF2 and FGF10 are of particular interest because uterine production of FGF2 and conceptus production of FGF10 intensify as elongation takes place in cattle and sheep. The objective of this work was to determine if FGF2 and FGF10 stimulate bovine trophectoderm migration during culture. Migration assays were conducted with CT1 cells, a trophectoderm line established from a bovine in vitro-produced blastocyst outgrowth. Cells were seeded on 8-μm pore Transwell inserts (Corning Inc., Corning, NY, USA; 50,000 cells/insert) and submerged in serum-free DMEM containing treatments (0, 0.5, 5, 50, and 500 ng mL-1 of recombinant bovine FGF2 or human FGF10). After 12 h, cells that migrated onto the lower surface were fixed, stained, and processed for counting using epifluorescence microscopy. Migrated cells were counted in 5 non-overlapping locations on each of 4 replicate Transwell inserts for each treatment. Experiments were repeated on at least 3 different occasions. Analysis of variance was completed. Differences in individual means were partitioned further by completing pair-wise comparisons. Supplementation with 5 or 50 ng mL-1 of FGF2 increased (P = 0.06 and P = 0.002, respectively) migration of CT1 cells when compared with controls (327 ± 17 or 485 ± 40 cells, respectively, v. 162 ± 16 cells). Supplementation with 500 ng mL-1 of FGF2 further increased (P < 0.02) migration when compared with controls and cells exposed to lower levels of FGF2 (548 ± 116 cells). FGF10 also stimulated CT1 migration. Supplementation with 0.5 ng mL-1 of FGF10 increased (P = 0.06) cell migration v. controls (254 ± 48 v. 184 ± 24 cells). Supplementation with 5 ng mL-1 further increased (P < 0.007) cell migration (373 ± 29 cells). Exposure to greater FGF10 concentrations did not further enhance cell migration. To summarize, both FGF2 and FGF10 promoted CT1 migration, suggestive of a potential function in regulating trophectoderm development, differentiation, and/or morphogenesis during peri-attachment conceptus development. FGF10 appeared to be more potent than FGF2 at mediating CT1 migration. The reason for this disparity has not been resolved but likely involves differences in ligand affinities to certain receptor subtypes. This project was supported by NRI Competitive Grant No. 2008-35203-19106 from the USDA-CSREES.


2020 ◽  
Vol 21 (13) ◽  
pp. 1344-1353
Author(s):  
Ali Talaei ◽  
Tahereh Farkhondeh ◽  
Fatemeh Forouzanfar

Schizophrenia is one of the most debilitating mental disorders around the world. It is characterized by neuroanatomical or biochemical changes. The role of the fibroblast growth factors (FGFs) system in schizophrenia has received considerable attention in recent years. Various changes in the gene expression and/or level of FGFs have been implicated in the etiology, symptoms and progression of schizophrenia. For example, studies have substantiated an interaction between FGFs and the signaling pathway of dopamine receptors. To understand the role of this system in schizophrenia, the databases of Open Access Journals, Web of Science, PubMed (NLM), LISTA (EBSCO), and Google Scholar with keywords including fibroblast growth factors, dopamine, schizophrenia, psychosis, along with neurotrophic were searched. In conclusion, the FGF family represent molecular candidates as new drug targets and treatment targets for schizophrenia.


2000 ◽  
Vol 5 (3) ◽  
pp. 179-190 ◽  
Author(s):  
PAUL V. WOOLLEY ◽  
SUSANNE M. GOLLIN ◽  
WAHEEB RISKALLA ◽  
SYDNEY FINKELSTEIN ◽  
DAVID F. STEFANIK ◽  
...  

2019 ◽  
Vol 20 (8) ◽  
pp. 852-870
Author(s):  
Hassan Dianat-Moghadam ◽  
Ladan Teimoori-Toolabi

Fibroblast growth factors (FGFs) are pleiotropic molecules exerting autocrine, intracrine and paracrine functions via activating four tyrosine kinase FGF receptors (FGFR), which further trigger a variety of cellular processes including angiogenesis, evasion from apoptosis, bone formation, embryogenesis, wound repair and homeostasis. Four major mechanisms including angiogenesis, inflammation, cell proliferation, and metastasis are active in FGF/FGFR-driven tumors. Furthermore, gain-of-function or loss-of-function in FGFRs1-4 which is due to amplification, fusions, mutations, and changes in tumor–stromal cells interactions, is associated with the development and progression of cancer. Although, the developed small molecule or antibodies targeting FGFR signaling offer immense potential for cancer therapy, emergence of drug resistance, activation of compensatory pathways and systemic toxicity of modulators are bottlenecks in clinical application of anti-FGFRs. In this review, we present FGF/FGFR structure and the mechanisms of its function, as well as cross-talks with other nodes and/or signaling pathways. We describe deregulation of FGF/FGFR-related mechanisms in human disease and tumor progression leading to the presentation of emerging therapeutic approaches, resistance to FGFR targeting, and clinical potentials of individual FGF family in several human cancers. Additionally, the underlying biological mechanisms of FGF/FGFR signaling, besides several attempts to develop predictive biomarkers and combination therapies for different cancers have been explored.


Sign in / Sign up

Export Citation Format

Share Document